CSI Market
Sign In | Register

Portola Pharmaceuticals inc (PTLA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access PTLA Annual Cash Flow →
Cash flow data covering Portola Pharmaceuticals inc–Mar 31 2019 offers a view into how Mar 31 2020's cash position has developed alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2020)
3 Months 		(Dec 31 2019) (Sep 30 2019) (Jun 30 2019) (Mar 31 2019)
Operating Activities
Income-68.77
Depreciation & amortization0.64
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Impairment of Intangible Assets, Finite-lived0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase-13.49
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation9.48
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction5.32
Increase Decrease In Prepaid Expense And Other Current Assets-2.33
Investment Income Amortization Of Premium-
Non Cash Interest-
Embedded Derivative Loss On Embedded Derivative-
Increase Decrease In Accrued Research And Development-2.02
Increase Decrease In Contract With Customer Liability-0.49
Allocated Share Based Compensation Expense Liability Classified Share Based Awards-
Manufacturing Process Transition Costs-
Operating Lease Cost1.17
Embedded Derivative Gain Loss On Embedded Derivative Net3.17
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts and Other Receivables6.14
Increase (Decrease) in Accounts Payable0.59
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-10.24
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets3.23
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-3.49
Discontinued operations0.00
Net Cash flow from Operating Activities-71.10
Investing Activities
Capital Expenditures-0.96
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities100.36
Short-term Investments Acq.0.00
Real Estate Investments0.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments-46.47
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities52.93
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.38
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Long Term Obligation To Collaborator-
Payments Of Long Term Obligation To Collaborator-0.28
Payments of Ordinary Dividends, Noncontrolling Interest0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.10
Effect of exchange rate on cash flow-0.02
Discontinued operations0.00
Free Cash Flow-72.06
Total Cash Flow-18.10
4 historic quarters locked

Sign in to unlock the full Portola Pharmaceuticals inc cash flow history.

Sign In Create Free Account

About PTLA Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.